A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.
Bottom Line: Incidence of any adverse events (AEs) was slightly higher (RR=1.05; 95% CI 0.93 to 1.2) while incidence of serious AEs was lower (RR=0.85; 95% CI 0.50 to 1.45) in the nicergoline compared with placebo group.Frequency of anxiety was significantly lower in nicergoline as compared with placebo (p=0.01).Other AEs including diarrhoea, gastric upset, dizziness and drowsiness were less frequent in the nicergoline group when compared with placebo/active drugs, but the difference was non-significant.
Affiliation: Department of Neurology and Psychiatry, University Hospital, Umberto I, University of Rome, Sapienza, Italy.Show MeSH
Related in: MedlinePlus
Mentions: Total withdrawals with nicergoline ranged from 0%2225 to 22.2%11 and from 0% to 27.8% with other comparator drugs/placebo. Six studies reported a lower number of patient withdrawals from the nicergoline group as compared with other comparator/placebo groups. Withdrawals due to AE were similar in the nicergoline group as compared with other groups across the studies (figure 2).
Affiliation: Department of Neurology and Psychiatry, University Hospital, Umberto I, University of Rome, Sapienza, Italy.